drugset / Trial / NCT02771405
Impact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCC
Phase 3
Completed
150 enrolled
National Hepatology & Tropical Medicine Research Institute
Cairo University · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The study will recruit 150 patients with HCV related HCC ,after HCC treatment the patients will undergo treatment with different regimens of DAAs.
Timeline
- Start
- 2016-03
- Primary completion
- 2017-12
- Completion
- 2018-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Daclatasvir | Small molecule | 60 mg | Oral |
| Subject | Ledipasvir | Small molecule | 90 mg | Oral |
| Subject | Ribavirin | Small molecule | 1000 mg | Oral |
| Subject | Ribavirin | Small molecule | 1200 mg | Oral |
| Subject | Simeprevir | Small molecule | 150 mg | Oral |
| Subject | Sofosbuvir | Small molecule | 400 mg | Oral |